AR104613A1 - THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER - Google Patents

THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER

Info

Publication number
AR104613A1
AR104613A1 ARP160101382A ARP160101382A AR104613A1 AR 104613 A1 AR104613 A1 AR 104613A1 AR P160101382 A ARP160101382 A AR P160101382A AR P160101382 A ARP160101382 A AR P160101382A AR 104613 A1 AR104613 A1 AR 104613A1
Authority
AR
Argentina
Prior art keywords
nsclc
methods
cancer
suffering
patient
Prior art date
Application number
ARP160101382A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR104613A1 publication Critical patent/AR104613A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos y composiciones terapéuticos y diagnósticos para el cáncer, por ejemplo, cáncer de pulmón de células no pequeñas (NSCLC). Métodos de tratamiento de NSCLC, métodos de determinación de si un paciente que está padeciendo de NSCLC probablemente responda al tratamiento que comprende un antagonista de unión al eje de PD-L1, métodos de predicción de la capacidad de respuesta de un paciente que está padeciendo de NSCLC al tratamiento que comprende un antagonista de unión al eje de PD-L1 y métodos para seleccionar una terapia para un paciente que está padeciendo de NSCLC, en base a niveles de expresión de un biomarcador de la presente (por ejemplo, niveles de expresión de PD-L1 en células tumorales y/o células inmunes infiltrantes de tumores). Reivindicación 42: El método de acuerdo con la reivindicación 41, en donde el anticuerpo se selecciona del grupo que consiste en: YW243.55.S70, MPDL3280A (atezolizumab), MDX-1105, MEDI4736 (durvalumab), y MSB0010718C (avelumab). Reivindicación 51: El método de acuerdo con la reivindicación 50, en donde el anticuerpo se selecciona del grupo que consiste en: MDX-1106 (nivolumab), MK-3475 (pembrolizumab), CT-011 (pidilizumab), MEDI-0680 (AMP-514), PDR001, REGN2810, y BGB-108.Therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). NSCLC treatment methods, methods for determining whether a patient who is suffering from NSCLC is likely to respond to treatment that comprises a PD-L1 axis binding antagonist, methods of predicting the responsiveness of a patient who is suffering from NSCLC to the treatment comprising a PD-L1 axis binding antagonist and methods for selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the present (eg, expression levels of PD-L1 in tumor cells and / or tumor infiltrating immune cells). Claim 42: The method according to claim 41, wherein the antibody is selected from the group consisting of: YW243.55.S70, MPDL3280A (atezolizumab), MDX-1105, MEDI4736 (durvalumab), and MSB0010718C (avelumab). Claim 51: The method according to claim 50, wherein the antibody is selected from the group consisting of: MDX-1106 (nivolumab), MK-3475 (pembrolizumab), CT-011 (pidilizumab), MEDI-0680 (AMP -514), PDR001, REGN2810, and BGB-108.

ARP160101382A 2015-05-12 2016-05-12 THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER AR104613A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160561P 2015-05-12 2015-05-12

Publications (1)

Publication Number Publication Date
AR104613A1 true AR104613A1 (en) 2017-08-02

Family

ID=59714266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101382A AR104613A1 (en) 2015-05-12 2016-05-12 THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER

Country Status (1)

Country Link
AR (1) AR104613A1 (en)

Similar Documents

Publication Publication Date Title
MX2023002251A (en) Therapeutic and diagnostic methods for cancer.
MX2022006075A (en) Therapeutic and diagnostic methods for cancer.
MX2020008882A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
BR112017020893A2 (en) method for cancer treatment
EA201792497A1 (en) ANTIBODIES TO GITR FOR DIAGNOSIS OF MALIGNANT TUMOR
BR112015007184A2 (en) combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
BR112017014551A2 (en) antibody, nucleic acid construct, expression vector, host cell, composition, methods for treating a disease, producing a bispecific antibody, and detecting the possible occurrence of crosslinking between cd3 and cd20-expressing cells in a derived sample of a patient, use of a bispecific antibody, and kit?
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
BR112014018331A8 (en) BIOMARKERS AND COMBINED THERAPIES USING ONCOLYTIC VIRUSES AND IMMUNOMODULATION
MX2018005071A (en) Treatment of small cell lung cancer with a parp inhibitor.
BR112017026709A2 (en) cancer treatment and diagnosis
BR112016007864A2 (en) Method for cancer prognosis and metastasis treatment
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
CY1120063T1 (en) HUMAN DLK-1 ANTIBODIES ACTING AGAINST TUMORS IN VIVO
MX2018001831A (en) Biomarkers for treatment of alopecia areata.
BR112016024143A2 (en) cancer treatment
EA201890649A1 (en) NEW BIOMARKERS AND METHODS OF CANCER TREATMENT
MX2019003569A (en) Methods for treating cancer with bavituximab based on levels of î²2-glycoprotein 1, and assays therefor.
EA201401353A1 (en) BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
MX2021003214A (en) Therapeutic and diagnostic methods for bladder cancer.